Intra-Tumoral Cancer Therapies in Melanoma
Intra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. Intra-Tumoral immunotherapy aims to use tumors as its own vaccine. By using tumors as a source of antigens expressed across multiple tumor clones, it aims to initiate local recruitment of immune cells into the tumor & subsequently prime T cells for a systemic polyclonal antitumor response addressing intra- & inter-tumoral heterogeneity.
Multiple Intra-Tumoral approaches such as immune-potentiating cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, OVs, plasmid DNA, etc., are under clinical development for melanoma patients.
DelveInsight presents a new addition to its newsletter edition that focuses on the Intra-Tumoral Cancer Therapies in Melanoma. The newsletter offers a complete picture of the Intra-Tumoral Therapies market landscape, ongoing clinical trials, and pipeline therapies that are expected to transform the Intra-Tumoral Cancer Therapies in the Melanoma market in the coming decade. Gain rich insights into Melanoma epidemiological insights, current treatment therapies, the evolution of Intra-Tumoral Cancer Therapies, FDA approved Intra-Tumoral Cancer Therapies, the clinical development landscape, expected FDA approval timelines of potential assets, potential game-changer drugs, KIQs, SWOT analysis, key Intra-Tumoral Cancer Therapies in the Melanoma market players and more details encompassed thoroughly in the newsletter.
Interested in knowing more about what upcoming years hold for the Intra-Tumoral Cancer Therapies in the Melanoma market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form towards the right.
Know more about What's covered:
- Melanoma Epidemiology
- Stage At Diagnosis
- Melanoma Market Size
- Unmet Needs
- Intra-tumoral Cancer Therapies
- Evolution of Intra-Tumoral Therapies
- Imlygic -talimogene laherparepvec (T-VEC)
- Amgen’s Hard Luck with Imlygic
- Clinical Development Landscape
- Expected FDA approval timelines of potential assets
- Potential Game Changers
- Key Intelligent Questions (KIQs)
- SWOT Analysis
- Key Intra-Tumoral Cancer Therapies in Melanoma Players